Date & Location
Tuesday, August 16, 2022, 8:41 AM - Saturday, August 16, 2025, 9:41 AM

Course Overview
The re-emergence of fentanyl has created a heightened need for clinicians to employ medications designed to treat opioid use disorder (MOUD) and implement harm reduction strategies. 

Target Audience
Specialties - ALL SPECIALTIES
Professions - Healthcare Administration, Industry, Nurse Practitioners, Other Healthcare Professionals, Pharmacists, Physicians


Objectives

After completing this activity, participants should be able to:


  1. Review epidemiology of opioid use disorder including the re-emergence of fentanyl
  2. Practice evidence-based medicine for patients with OUD by using medications for opioid use (MOUD) disorder and harm reduction strategies
  3. Analyze the benefits of short-acting opioids as a tool for withdrawal and pain in patients with active OUD

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physicians: Penn Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The activity awards 1.0 NCPD hours

Pharmacists: This knowledge-based activity is approved for 1.0 ACPE contact hours of continuing pharmacy education credit. UAN JA0000324-0000-22-035-H04-P

Opioid Education: This activity is approved for 1.0 hours in Opioid Education. 


Credits
AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance / Participation (1.00 hours), NCPD Hours (ANCC) (1.00 hours), Opioid Education (1.00 hours), American Academy of Physician Assistants (1.00 hours)